dc.contributor.author |
Kleynhans, Janke
|
|
dc.contributor.author |
Grobler, Anne Frederica
|
|
dc.contributor.author |
Ebenhan, Thomas
|
|
dc.contributor.author |
Sathekge, Mike Machaba
|
|
dc.contributor.author |
Zeevaart, Jan-Rijn
|
|
dc.date.accessioned |
2018-09-13T10:47:38Z |
|
dc.date.issued |
2018-10 |
|
dc.description.abstract |
INTRODUCTION : Drug delivery systems are entities designed to alter the biological behaviour of the pharmaceutical active ingredients that they carry in order to afford more beneficial biodistribution and safety profiles. Many problems currently faced by the field of nuclear medicine (e.g. developing new theranostic agents, utilizing multimodal imaging platforms and providing targeted delivery) can be facilitated by applying drug delivery systems to radiopharmaceuticals that have been proven successful in other medical fields. This review describes the advancements being made towards this goal. AREAS COVERED : All aspects of drug delivery systems (liposomes, nanoparticles, microspheres) in the field of nuclear medicine are discussed. Only systems with foreseen or confirmed clinical applications in nuclear medicine are discussed, not instances where nuclear imaging is merely a tool to evaluate the biodistribution of novel delivery technologies. CONCLUSIONS : Great advancements have been made with the development of novel systems incorporating nuclear entities in drug delivery systems, with the possibility of reshaping the nuclear medicine landscape. Nonetheless, translation from preclinical evaluations to clinical use is lacking and serious investment needs to be made towards this goal. |
en_ZA |
dc.description.department |
Nuclear Medicine |
en_ZA |
dc.description.embargo |
2019-10-10 |
|
dc.description.librarian |
hj2018 |
en_ZA |
dc.description.sponsorship |
J. Kleynhans received financial assistance from the National Research Foundation (NRF) of South Africa (grant number SFH 14070573914) as well as the Nuclear Technologies in Medicine and Biosciences Initiative (NTeMBI)- a national technology platform developed and managed by the South African Nuclear Energy Corporation (Necsa) and funded by the Department of Science and Technology. |
en_ZA |
dc.description.uri |
http://www.elsevier.com/locate/jconrel |
en_ZA |
dc.identifier.citation |
Kleynhans, J., Grobler, A.F., Ebenhan, T. et al. 2018, 'Radiopharmaceutical enhancement by drug delivery systems : a review', Journal of Controlled Release. vol. 287, pp. 177-193. |
en_ZA |
dc.identifier.issn |
0168-3659 (print) |
|
dc.identifier.issn |
1873-4995 (online) |
|
dc.identifier.other |
10.1016/j.jconrel.2018.08.008 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/66558 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Elsevier |
en_ZA |
dc.rights |
© 2018 Elsevier B.V. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Journal of Controlled Release. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Journal of Controlled Release, vol. 287, pp. 177-193, 2018. doi : 10.1016/j.jconrel.2018.08.008. |
en_ZA |
dc.subject |
Drug carrier systems |
en_ZA |
dc.subject |
Multi-modality imaging |
en_ZA |
dc.subject |
Nuclear medicine |
en_ZA |
dc.subject |
Radiopharmaceuticals |
en_ZA |
dc.subject |
Theranostics |
en_ZA |
dc.subject |
Controlled drug delivery |
en_ZA |
dc.subject |
Drug delivery system |
en_ZA |
dc.subject |
Clinical application |
en_ZA |
dc.subject |
Active ingredients |
en_ZA |
dc.subject |
Targeted drug delivery |
en_ZA |
dc.subject |
Medical problems |
en_ZA |
dc.subject |
Medical imaging |
en_ZA |
dc.subject |
Liposomes |
en_ZA |
dc.title |
Radiopharmaceutical enhancement by drug delivery systems : a review |
en_ZA |
dc.type |
Postprint Article |
en_ZA |